Titre
Off-the-shelf allogeneic natural killer cells for the treatment of COVID-19.
Type
article
Institution
Externe
Auteur(s)
Liu, W.L.
Auteure/Auteur
Kampouri, E.
Auteure/Auteur
Bui, J.K.
Auteure/Auteur
Sekhon, M.K.
Auteure/Auteur
Tercero, A.
Auteure/Auteur
Finlay, D.
Auteure/Auteur
Asghedom, L.H.
Auteure/Auteur
Romasanta, G.R.
Auteure/Auteur
Rice, N.T.
Auteure/Auteur
Ranjbaran, F.
Auteure/Auteur
Stoltzman, C.
Auteure/Auteur
Cook, J.
Auteure/Auteur
Blake, J.
Auteure/Auteur
Delaney, C.S.
Auteure/Auteur
Hill, J.A.
Auteure/Auteur
Liens vers les personnes
ISSN
2329-0501
Statut éditorial
Publié
Date de publication
2024-12-12
Volume
32
Numéro
4
Première page
101361
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Low levels and function of natural killer (NK) cells are associated with increased coronavirus disease 2019 (COVID-19) severity. NK cell immunotherapy may improve immune function to reduce infection severity. We conducted a first-in-human, open-label, phase 1, dose-escalating (100 × 10 <sup>6</sup> , 300 × 10 <sup>6</sup> , or 900 × 10 <sup>6</sup> cells) study of a single dose of DVX201, a cord-blood-derived allogeneic NK cell therapy, in hospitalized patients with COVID-19. Participants were followed for 28 days. The maximum allowed steroid dose for eligibility was up to 0.5 mg/kg prednisone (or equivalent) daily. We enrolled nine participants, 3 per dose level. Eight participants had ≥1 comorbidity associated with increased COVID-19 severity, three of whom had a hematologic malignancy. Infusions were well tolerated, with no treatment-related adverse events. There was no evidence of inflammatory complications related to infusions. Peripheral blood NK cells generally increased after infusion, peaking by day 7. The median time from infusion to discharge was 2 days (range: 1-13). Two patients (both with acute lymphoblastic leukemia) were readmitted with recurrent COVID-19. This trial demonstrates the safety of allogeneic NK cell immunotherapy as a potential antiviral. Larger controlled trials are needed to establish efficacy.
PID Serval
serval:BIB_3E4716357D95
PMID
Open Access
Oui
Date de création
2025-01-10T10:23:31.102Z
Date de création dans IRIS
2025-05-20T15:32:17Z